A case of osteonecrosis of the jaw related to Bevacizumab, a recombinant humanized monoclonal antibody targeting VEGF

YASUI Takazumi, ONIZAWA Katsuhiro, HYODO Tomoko, IWASAKI Ryotaro, ASODA Seiji, KAWANA Hiromasa

doi:10.11277/stomatology.60.16

Bibliographic Information

Other Title

抗VEGFモノクロナール抗体ベバシズマブの関与が疑われた顎骨壊死の1例
コウVEGF モノクロナールコウタイベバシズマブノカンヨガウタガワレタガクコツエシノ 1レイ

Search this article

Abstract

Bevacizumab, a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), intercepts the supply of blood which is indispensable for cancer to proliferate and metastasize to the whole body. We report a case of osteonecrosis of the jaw during chemotherapy using Bevacizumab in a 64-year-old woman with unresectable colorectal cancer. After surgical treatment for sigmoid colorectal cancer had been performed in the surgery department of another hospital, multiple lung and bone metastases were discovered. Therefore, she received Bevacizumab therapy combined with another chemotherapy. At the initial examination, there was exposed bone in the right mandibular lingual gingiva of the third molar region. This bone was isolated as a sequestrum and was easily removed. The surgical wound became completely covered with mucosal epithelia. There was no evidence of recurrence for 10 months after treatment.<br>We suspect that this osteonecrosis of the jaw was caused by the antiangiogenic property of Bevacizumab.

Journal

Journal of The Japanese Stomatological Society

Journal of The Japanese Stomatological Society 60 (1), 16-22, 2011

Japanese Stomatological Society

Keywords

Details 詳細情報について

Export

A case of osteonecrosis of the jaw related to Bevacizumab, a recombinant humanized monoclonal antibody targeting VEGF

Bibliographic Information

Search this article

Abstract

Journal

Citations (1)*help

References(16)*help

Related Projects

Keywords

Details 詳細情報について

Export

Report a problem